Key result
High dose aspirin >6 months post-PED was associated with fewer permanent thrombotic and hemorrhagic events, while platelet function testing showed no significant association with symptomatic events.
Why the study?
Does antiplatelet therapy dose, duration, and platelet function testing affect hemorrhagic and thrombotic complications in patients with cerebral aneurysms treated with the pipeline embolization device?
Meta-Analysis
Yes
Does antiplatelet therapy dose, duration, and platelet function testing affect hemorrhagic and thrombotic complications in patients with cerebral aneurysms treated with the pipeline embolization device?
In patients treated with the pipeline embolization device for cerebral aneurysms, high-dose aspirin for >6 months and loading doses of dual antiplatelet therapy are associated with fewer complications, whereas platelet function testing has no significant impact.
Answers are grounded in this paper and cite their sources.
High-dose aspirin >6 months post-PED may reduce events; supports extended duration while challenging platelet function testing.
PURPOSE: The pipeline embolization device (PED) necessitates dual antiplatelet therapy (APT) to decrease thrombotic complications while possibly increasing bleeding risks. The role of APT dose, duration, and response in patients with hemorrhagic and thromboembolic events warrants further analysis. METHODS: A PubMed and Google Scholar search from 2009 to 2014 was performed using the following search terms individually or in combination: pipeline embolization device, aneurysm(s), and flow diversion, excluding other flow diverters. Review of the bibliographies of the retrieved articles yielded 19 single and multicenter studies. A statistical meta-analysis between aspirin (ASA) dose (low dose ≤160 mg, high dose ≥300 mg), loading doses of APT agents, post-PED APT regimens, and platelet function testing (PFT) with hemorrhagic or thrombotic complications was performed. RESULTS: ASA therapy for ≤6 months post-PED was associated with increased hemorrhagic events. High dose ASA ≤6 months post-PED was associated with fewer thrombotic events compared with low dose ASA. Post-PED clopidogrel for ≤6 months demonstrated an increased incidence of symptomatic thrombotic events. Loading doses of ASA plus clopidogrel demonstrated a decreased incidence of permanent symptomatic hemorrhagic events. PFT did not show a statistically significant relationship with symptomatic hemorrhagic or thrombotic complications. CONCLUSIONS: High dose ASA >6 months is associated with fewer permanent thrombotic and hemorrhagic events. Clopidogrel therapy ≤6 months is associated with higher rates of thrombotic events. Loading doses of ASA and clopidogrel were associated with a decreased incidence of hemorrhagic events. PFT did not have any significant association with symptomatic events.
No takes yet. Share an insight, caveat, or question.
Skukalek et al. (2014) conducted a meta-analysis in Cerebral aneurysms. Antiplatelet therapy and platelet function testing vs. Alternative antiplatelet regimens was evaluated on Hemorrhagic or thrombotic complications. High dose aspirin >6 months post-PED was associated with fewer permanent thrombotic and hemorrhagic events, while platelet function testing showed no significant association with symptomatic events.
Synapse has enriched 10 related papers. Consider them for comparative context: